

Fiscal Note 2017 Biennium

Bill # SB	30007		Title: Revise	and extend the prescripti	on drug registry fee
Primary Sponsor: Wo	ebb, Roger		Status: As Int	roduced	
☐ Significant Loca	ll Gov Impact [☐ Needs to be included ☐ Significant Long-Te		☐ Technical Concerns ☐ Dedicated Revenue F	orm Attached
Expenditures:		FISCAL ST FY 2016 <u>Difference</u>	UMMARY FY 2017 <u>Difference</u>	FY 2018 <u>Difference</u>	FY 2019 <u>Difference</u>
General Fund State Special Revenue		\$0	\$0	\$0	\$0
Revenue: General Fund State Special Revenue		\$0 \$232,920	\$0 \$239,580	\$0	\$0
Net Impact-General Fund Balance:		\$0	\$0	\$0	\$0

Description of fiscal impact: SB 7 extends the sunset date for the Prescription Drug Registry and the associated revenue.

FISCAL ANALYSIS

Assumptions:

- 1. This legislation will revise language regarding the funding of the Prescription Drug Registry and will extend the termination date through the end of FY 2017.
- 2. The registry presently collects fees from pharmacists, physicians, dentists, optometrists, naturopathic physicians, physician assistants, and advanced practice registered nurses with prescriptive authority. The present fee set by statute is \$15 per licensee. This legislation would allow an increase up to \$30 per licensee, based on fees being set commensurate with costs.
- 3. It is estimated that in FY 2016 there will be 9,705 licensees subject to fee payment requirements, who may also qualify to use the registry. Of this group, it is estimated that up to 20% or 1,941 may not comply with registry fee payment requirements, or may attest that the fee does not apply to them as they do not prescribe or dispense controlled substances. It is assumed the registry will collect a fee from the remainder totaling \$232,920 (7,764 registry users x \$30).
- 4. There is anticipated to be 9,982 licensees subject to the fee payment in FY 2017. Allowing for the same compliance rate used in assumption #3, the registry is estimated to collect \$239,580 in FY 2017.

- 5. The present statute terminates the registry in July 1, 2015. This legislation would extend that date to June 30, 2017. Revenue estimates are not noted beyond that point.
- 6. The revenue generated by SB 7 will be applied towards funding the Prescription Drug Registry program in the Department of Labor and Industry. The expenditures for that program are included in the Executive Budget and therefore not reflected in this fiscal note.

	FY 2016	FY 2017	FY 2018	FY 2019				
	Difference	Difference	Difference	Difference				
Fiscal Impact:								
Expenditures:								
Personal Services	\$0	\$0	\$0	\$0				
Operating Expenses	\$0_	\$0	\$0	\$0				
TOTAL Expenditures	\$0	\$0	\$0	\$0				
Funding of Expenditures:								
General Fund (01)	\$0	\$0	\$0	\$0				
State Special Revenue (02)		\$0	\$0	\$0_				
TOTAL Funding of Exp	\$0	\$0	<u>\$0</u>	\$0				
Revenues:								
General Fund (01)	\$0	\$0	\$0	\$0				
State Special Revenue (02)	\$232,920	\$239,580	\$0	\$0				
TOTAL Revenues	\$232,920	\$239,580	\$0	\$0				
Net Impact to Fund Balance (Revenue minus Funding of Expenditures):								
General Fund (01)	\$0	\$0	\$0	\$0 °				
State Special Revenue (02)	\$232,920	\$239,580	\$0	\$0				

Sponsor's Initials

-6-15

Budget Director's Initials

Date